JAN 0 5 2001 E

526 Rec'd PCT/PTO

5 JAN 2001

RECEIVED

Practitioner's Docket No. 700157-48436

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sodroski et al.

Group:

Application No.:

09/446,820

Examiner:

Filed:

November 10, 1998

For:

STABILIZED PRIMATE LENTIVIRE STABILIZED

GLYCOPROTEINS

DO JAN 2001

Assistant Commissioner for Patents

Washington, D.C. 20231

Legal Staff

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that the following correspondence:

- 1. Information Disclosure Statement (3 pgs);
- 2. Form PTO 1449 (6 pgs);
- 3. References AA, CA-GX (129 refs.);
- 4. Return Receipt Postcard;

is on the date shown below being:

MAILING

X deposited with the United States Postal Service and with sufficient postage as first class mail in a box addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 26, 2000

FACSIMILE

transmitted by facsimile to the Patent Trademark Office.

gignature

Carline L. Lemoine

(type or print name of person certifying)



Docket No. 70015

IN THE UNITED STATES PATENT AND TRADEMARK OFF

Applicants: Sodroski et al.

Group:

Serial No.:

09/446,820

Examiner:

Filed:

November 10, 1998

For:

STABILIZED PRIMATE LENTIVIRUS ENVELOPE

GLYCOPROTEINS

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

within three (3) months of the Filing Date or before the _X_ **(1)** mailing date of the First Office Action on the merits; or

B445257.1

(2) within three months of the mailing date of the PCT
 International Search Report; or
 (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or
 (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

are enclosed herewith; and
 have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Ronald I. Eisenstein (Reg. 30,628)

NIXON PEABODY LLP

101 Federal Street Boston, MA 02110

(617) 345-6057

Date: December 26, 2000




FORM P	TO-14	149	2	DOCKET NO.	: 700157/4	8436 SERI	AL NO.: 09/	446,8 2 0		
INFORMATION DISCLOSO					APPLICANT(S): Sodroski et al.					
				FILING DATE	FILING DATE: 11/10/98		NO.:			
			UNITED ST	ATES PATENT	DOCUMI	ENTS	_	म्मि ७		
EXAM. INITIAL S		DOCUME NT DATE NUMBER		INVENTOR/ ASSIGNEE	CLASS	SUBCLAS	S FILING APPRO	DATE IF PEATE PEATE		
	AA 45,817,316 Oct. 6, 199		Oct. 6, 1998					900		
			FORE	IGN PATENT DOO	CUMENTS					
		DOCUME NT NUMBER	DATE	COUNT	COUNTRY		SUBCLASS	TRANSL ATION YES/NO		
	BA									
BB			-							
	BC									
	BD									
	BE									
OTH	CAL	Alkhatib, G	., et al., Scienc	G AUTHOR, TIT ce 272:1955-1958 228:1091-1093 (1	3 (1996)	PERTINE	ENT PAGES,	ETC.)		
	CC Altschul, SF., et al., Nucleic Acids Res. 25: 3389-3402 (1997)									
	CD Arendrup, et al., <i>J. AIDS</i> 5:303-307 (1992)									
	CE, Arthos, J., et al., Cell 57:469 (1989)									
	CF,	CF Baggioline, M., et al., Adv. Immunol. 55:97-179 (1994)								
	CG	CG Barre-Sinousi, F., et al., Science 220:868-871 (1983)								
	CH Perkower, et al., J. Exp. Med. 170:1681-1695 (1989)									
	CT Berman, PW., et al., Nature 345:622-625 (1990)									
	CJ Binley, J., et al., AIDS Res. Hum. Retroviruses, 14:191-198 (1997) CK Bolmstedt, A., et al., J. AIDS 12:213-220 (1996) CL Brodsky, MH., et al., J. Immunol. 144:3078-3086 (1990)									
	CM-	Bruck, et al	., Vaccine 12:	1141-1148 (1994))					
		1								

FORM PTO-1449 INFORMATION DISCLOSURE	OOCKET NO.: 700157/48436 SERIAL NO.: 09/446,820
INFORMATION DISCLOSURE	APPLICANT(S): Sodroski et al.
STATEMENT	FILING DATE: 11/10/98 GROUP NO.:
CN Bullough, P., et al., Nature 37	1:37-43 (1994)
CO Burton, et al., Science 266:10	24-1027 (1994)
CR Cao, J., et al., J. Virol. 71:980	8-9812 (1997)
CQ Carr, CM., et al., Cell 73:823	832 (1993)
CR Chan, DC., et al., Cell 89:263	-273 (1997)
CS Chen, CH., et al., J. Virol. 69:	3771-3777 (1995)
CT Zhen, Z., et al., J. Virol. 71:2'	705-2714 (1997)
CU Cheng-Mayer, C., et al., Scien	ace 240:80-82 (1988)
CV Choe, H., et al., Cell 85:1135	-1148 (1996)
CW Clark, SJ, et al., N. Engl. J. M.	Ted. 324:950-960 (1991)
CX Cocchi, F., et al., Nature Med	. 2:1244-1247 (1996)
CY\ Locchi, F., et al., Science 270	:1811-1815 (1995)
CZ Connor, R., et al., J. Exp. Med	d. 185:628 (1997)
DAi Connor, RI., et al., J. Virol. 6'	7:1772-1778 (1993)
DB Coombs, RW., et al., N. Engl	. J. Med. 321:1626-1631 (1989)
DC Cordonnier, A., et al., Nature	340:571-574 (1989)
DD D'Souza, et al., J. Infect. Dis.	175: 1056-1062 (1997)
DE Daar, ES., et al., N. Engl. J. N.	ded. 324:961-964 (1991)
DF. Daar, et al., Proc. Natl. Acad.	· · · · · · · · · · · · · · · · · · ·
DG Dalgleish, AG., et al., Nature	312:763-767 (1984)
DH Dalum, et al., Mol. Immunol.	34:11-13-1120 (1997)
DI Davidson, et al., Nat. Genet 3	:219 (1993)
DJ Dean, M., et al., Science 273:	1856-1862 (1996)
DK Dempsey, P., et al., Science 2	71:348-350 (1996)
DL Deng, HK., et al., Nature 381	:661-666 (1996)
DM Doranz, BJ., et al., Cell 85:11	49-1158 (1996)
DN Dragic, T., et al., Nature 381:	667-673 (1996)
DO Earl, PL., et al., J. Virol. 65:2	047-2055 (1991)

FORM PTO-1449	OOCKET NO.: 700157/48436 SERIAL NO.:	09/446,820			
INFORMATION DISCLOSURE	APPLICANT(S): Sodroski et al.	Ω			
STATEMENT	FILING DATE: 11/10/98 GROUP NO.:	CENI			
DP Earl, PL., et al., Proc. Natl.	Acad. Sci. USA 87:648-652 (1990)				
DQ Emini, et al., Nature 355:72	DQ Æmini, et al., <i>Nature</i> 355:728-730 (1991) DR Æmini, et al., <i>Ann. Inter. Med.</i> 124:654-663 (1996)				
DR Fauci, AS., et al., Ann. Inter					
DS Feng, Y., et al., Science 272	2001				
DT Fenyo, E., et al., J. Virol. 62	DT Fenyo, E., et al., J. Virol. 62:4414-4419 (1988)				
DU Freed, E., et al., Proc. Natl.	DU Freed, E., et al., Proc. Natl. Acad. Sci. USA 87:4650-4654 (1990)				
DV J ung, et al., <i>J. Virol.</i> 66:848	DV Jung, et al., J. Virol. 66:848-856 (1992)				
DW Gallo, RC., et al., Science 2	DW Callo, RC., et al., Science 224:500-503 (1984)				
DX Gegerfelt, et al., Virology 18	85:162-168 (1991)				
DY Geller, AI., et al., J. Neuroc	DY Geller, AI., et al., J. Neurochem 64:487 (1995)				
DZ Geller, AI., et al., Proc Natl	l. Acad. Sci. U.S.A. 87:1149 (1990)				
EA VGeller, AI., et al., Proc Natl	EA VGeller, AI., et al., <i>Proc Natl. Acad. Sci. U.S.A.</i> 90:7603 (1993)				
EB Gerard, N., et al., Curr. Opi	EB Gerard, N., et al., Curr. Opin. Immunol. 6:140-145 (1994) EC Girard, et al., Proc. Natl. Acad. Sci. USA 88:542-546 (1991)				
EC Girard, et al., Proc. Natl. Ac					
ED Forny, et al., J. Virol. 66:75	538-7542 (1992)				
EE Haigwood, et al., AIDS Res.	. Hum. Retro. 6:855-869 (1990)				
EF Haigwood, et al., J. Virol. 6	66:172-182 (1992)				
EG Ho, DD., et al., N. Engl. J. I	Med. 321:1621-1625 (1989)				
EH Ho, et al., J. Virol. 65:489-4	493 (1991)				
El Javaherian, et al., Science 2	50:1590-1593 (1990)				
EJ Xang, et al., Proc. Natl. Acc	ad. Sci. USA 88:6171-6175 (1991)				
EK Kaplitt, MG., et al., Nat. Ge	enet. 8:148 (1994)				
ELV Karlsson, G., et al., J. Virol.	. 71:4218 (1997)				
EM Klaniecki, et al., AIDS Res.	Hum. Retro. 7:791-798 (1991)				
EN Klatzmann, D., et al., Natur	re London 312:767-68 (1984)				
EO Kowalski, M., et al., Science	e 237:1351-1355 (1987)				
EP, Lasky, L., et al., Cell 50:97:	5-985 (1987)				
EQ LeGal LaSalle, et al., Science	ce 259: 988 (1993)				
					

	PARTY 0 5 ANY	وم م			
FORM PTO-		5/ DOCKET NO.: 700157/48	436 SERIAL NO ·	09/246,	820 <u> </u>
FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Sodroski		$\frac{\overline{\sigma}}{\sigma}$	
		FILING DATE: 11/10/98	GROUP NO.:	3	
E	R Leonard, CK., et al., J. Biol.	Chem. 265:10373-10382 (1990)	<u> </u>	
Е	S Liu, R., et al., Cell 86:367-3	78 (1996)	- 5,	1600/2900	
E	ET, Lu, M., et al., Nature Structural Biol. 2:1075-1082 (1995)				
E	Warcon, L., et al., J. Virol. 7	71:2522-2527 (1997)			
E	Matthews, et al., Proc. Nat.	Acad. Sci. USA 83:9709-9	713 (1986)		
E	WilMcKeating, et al., J. Virol. 6	57:4932-4944 (1993)			
E	X McKeating, et al., Virology	190:134-142 (1992)			
E,	Y Moebius, U., et al., J. Exp. A	Med. 176:507-517 (1982)			
E	Z Moore, et al., J. Virol. 69:10	1-109 (1995)			
FA	A. Moore, et al., J. Virol. 67:61	36-6151 (1993)			
FI	Moore, et al., J. Virol. 67:86	3-875 (1993)			
F	Compore, et al., J. Virol. 69:12	2-133 (1995)			
FI	Moore, et al., J. Virol. 70:18	63-1872 (1996)			
F	E Moore, J., et al., J. Virol. 68	:469-484 (1994)			
F	F Moore, J., et al., J. Virol. 68	:8350-8364 (1994)			
FC	G Muster, et al., J. Virol. 67:66	642-6647 (1993)			
FI	Myers, G., et al., "Human R Mucleic Acid and Amino Ac		_	•	
F	Nara, et al., J. Virol. 64:3779	9-3791 (1990)			
F	Johno, et al., Proc. Natl. Aca	d. Sci. USA 88:10726-107	29 (1991)		
FI	K Olshevsky, U., et al., J. Viro	<i>l</i> . 64:5701-5707 (1990)			
F	Leterson, A., et al., Cell 54:6	55-72 (1988)			
FI	M Pinter, A., et al., J. Virol. 63	:2674-2679			
F	N Pollard, S., et al., EMBO J.	11:585-591 (1992)			
FO	Posner, et al., J. Immunol. 10	6:4325-4332 (1991)			
F	Premack, BA., et al., Nature	Medicine 11:1174-1178 (1	1996)		
	$Q \not P$ rofy, et al., <i>J. Immunol.</i> 14				
F	R Roben, P., et al., J. Virol. 68	:4821-4828 (1994)			



O I DE SCILL	,		-		
FORM PTO-1449	DOCKET NO.: 700157/48436 SERIAL NO.: 09/4452			20	77
INFORMATION DISCLOSURE	APPLICANT(S): Sodroski et al.		<u> </u>	BE	ñ
STATEMENT	FILING DATE: 11/10/98	GROUP NO.:	NIE.	<u>د</u>	\bigcirc
GU Wyatt, R., et al., J. Virol. 71:9722-9731 (1997)			R 16		П
GV Wang, et al., J. Virol. 69:200	4 (1995)		NTER 1600/2900	200	\leq
GW Zhang, L., et al., Nature 383	:768 (1996)		900	Ü	יל כ
GX Zhu, T., et al., Science 261:1179-1181 (1993)					
	e de la companya de l				
EXAMINER:		DATE:			